Towards Clinical Proton Minibeam Radiation Therapy (pMBRT): Development of Clinical pMBRT System Prototype and pMBRT-Specific Treatment Planning Method

PURPOSE/OBJECTIVE(S)

Proton minibeam radiation therapy (pMBRT) is an emerging spatially fractionated RT (SFRT) modality that can provide very high therapeutic index compared to conventional radiotherapy methods and clinically-available SFRT methods (GRID and LATTICE). The biological data collected thus far encourage the preparation of clinical trials in pMBRT. This work is to facilitate the clinical translation of pMBRT by developing (1) the first clinical pMBRT system prototype worldwide, readily available for both small-animal biology studies and large-animal pMBRT trials; (2) pMBRT-specific treatment planning method with peak-valley dose ratio (PVDR) optimization capability for large animal and patient pMBRT trials, which is currently unavailable.

MATERIALS/METHODS

The pMBRT system is based on clinically-used pencil-beam-scanning proton machine equipped with large-field clinical-size pMBRT collimator, pMBRT-dedicated treatment planning system, and KV/CBCT imaging guidance. The multi-slit brass collimator has 10 × 10 cm field size, 0.4mm width per slit and 4 mm center-to-center distance. The divergence of slits is tailed to the divergence of the proton beam. A unique universal collimator design is implemented, so that we can keep the outer fitting to the snout and conveniently inter-change collimators as needed. The pMBRT-specific treatment planning method jointly optimizes PVDR and dose objectives, to meet a minimal PVDR threshold and maximize PVDR, to avoid the situations where meeting dose objectives can compromise PVDR when PVDR were not optimized. In addition, the survival fraction for organs at risk is also optimized. The dose calculation engine is based on the Monte Carlo method using TOPAS. The optimization algorithm utilizes total variation and L1 sparsity regularization to maximize PVDR and iterative convex relaxation method to solve the optimization problem.

RESULTS

Monte Carlo simulations via TOPAS were performed to design this large-field multi-slit collimator, using the beam structure and the beam data specific to our proton system, with mean dose rate of 8 Gy/min under clinical condition with the collimator in place. The feasibility of using this pMBRT system for small-animal studies has been demonstrated, with customized 3D printed holder for immobilizing small animals, on-board KV imaging system for accurate small-animal positioning, and the GAFchromic film for verifying radiation dose and PVDR. On the other hand, the efficacy of pMBRT-specific treatment planning method (with PVDR optimization capability) to improve PVDR has been demonstrated using retrospective patient planning studies in comparison with standard proton treatment planning method (without PVDR optimization capability).

CONCLUSION

The initial development of a clinical pMBRT system prototype and pMBRT-specific treatment planning method of PVDR optimization capability has been completed with ongoing efforts to make this system ready for large-animal pMBRT studies.

Virtual-Collimator Based Spatial Dose Modulation for Proton GRID Therapy

PURPOSE/OBJECTIVE(S)

Compared to conventional proton therapy, the proton GRID therapy can substantially improve normal tissue protection (with the delivery of spatially-modulated peak-valley dose pattern to normal tissues) while maintaining the tumor control efficacy (with the delivery of uniform dose pattern to tumor targets). The realization of proton GRID often relies on the use of physical collimators to shape the spatial dose distribution. However, the physical collimator may increase neutron dose, decrease delivery efficiency, and limit the freedom for patient positioning. Here we propose a virtual-collimator (VC) method for proton GRID. This new approach can generate peak-to-valley pattern with high peak-to-valley dose ratio (PVDR), without using a physical collimator.

MATERIALS/METHODS

The principle behind the VC method to modulate the spatial dose distribution consists of two major steps: (1) the primary beam is essentially halved, i.e., the beamlets are interleaved, so that the organ-at-risk (OAR) plane has the peak-valley dose pattern, while the target plane also has the valley dose; (2) the complementary beam is added with half complementary beamlets to fill in the previously valley-dose positions at the target plane, so that the target dose is uniform, while on the other hand, the complementary beam is angled slightly from the primary beam, so that the OAR still has the peak-valley dose pattern. Moreover, on top of VC, we also utilize sparsity regularization method using total variation and L1 sparsity (TVL1) to further jointly optimize PVDR and dose objectives, namely VC-TVL1.

RESULTS

VC and VC-TVL1 were validated in comparison with conventional proton GRID treatment planning method via IMPT ("CONV") and TVL1-based proton GRID treatment planning method without VC ("TVL1"), for a prostate case with single-beam (270° only) or two-beam (90° and 270°) scenarios. As shown in the table, the results show that VC can indeed modulate spatial dose with higher PVDR than CONV or even TVL1. VC had higher spatial modulation frequency with smaller peak-to-peak distance than TVL1. Moreover, VC+TVL1, as the synergy of VC and TVL1, further improved PVDR from VC or TVL1 alone.

CONCLUSION

A new way to deliver proton GRID therapy without a physical collimator is developed using the VC method. The VC method can be synergized with TVL1 optimization algorithm to further jointly optimize PVDR and dose objectives.

A filtering approach for PET and PG predictions in a proton treatment planning system

Positron emission tomography (PET) and prompt gamma (PG) detection are promising proton therapy monitoring modalities. Fast calculation of the expected distributions is desirable for comparison to measurements and to develop/train algorithms for automatic treatment error detection. A filtering formalism was used for positron-emitter predictions and adapted to allow for its use for the beamline of any proton therapy centre. A novel approach based on a filtering formalism was developed for the prediction of energy-resolved PG distributions for arbitrary tissues. The method estimates PG yields and their energy spectra in the entire treatment field. Both approaches were implemented in a research version of the RayStation treatment planning system. The method was validated against PET monitoring data and Monte Carlo simulations for four patients treated with scanned proton beams. Longitudinal shifts between profiles from analytical and Monte Carlo calculations were within -1.7 and 0.9 mm, with maximum standard deviation of 0.9 mm and 1.1 mm, for positron-emitters and PG shifts, respectively. Normalized mean absolute errors were within 1.2 and 5.3%. When comparing measured and predicted PET data, the same more complex case yielded an average shift of 3 mm, while all other cases were below absolute average shifts of 1.1 mm. Normalized mean absolute errors were below 7.2% for all cases. A novel solution to predict positron-emitter and PG distributions in a treatment planning system is proposed, enabling calculation times of only a few seconds to minutes for entire patient cases, which is suitable for integration in daily clinical routine.

Validation of the analytical irradiator model and Monte Carlo dose engine in the small animal irradiation treatment planning system µ-RayStation 8B

Dose calculation in preclinical context with a clinical level of accuracy is a challenge due to the small animal scale and the medium photon energy range. In this work, we evaluate the effectiveness and accuracy of an analytical irradiator model combined with Monte Carlo (MC) calculations in the irradiated volume to calculate the dose delivered by a modern small animal irradiator. A model of the XRAD225Cx was created in µ-RayStation 8B, a preclinical treatment planning system, allowing arc and static beams for seven cylindrical collimators. Calculations with the µ-RayStation MC dose engine were compared with EBT3 measurements in water for all static beams and with a validated GATE model in water, heterogeneous media and a mouse CT. The GATE model is a complete MC representation of the XRAD225Cx. In water, µ-RayStation calculations, compared to GATE calculations and EBT3 measurements, agreed within a maximal error of 3.2% (mean absolute error of 0.6% and 0.8% respectively) and maximal distance-to-agreement (DTA) was 0.2 mm at 50% of the central dose. For a 5 mm static beam in heterogeneous media, the maximal absolute error between µ-RayStation and GATE calculations was below 1.3% in each medium and DTA was 0.1 mm at interfaces. For calculations on a mouse CT, µ-RayStation and GATE calculations agreed well for both static and arc beams. The 2D local gamma passing rate was  >98.9% for 1%/0.3 mm criteria and  >92.9% for 1%/0.2 mm criteria. Moreover, µ-RayStation reduces calculation time significantly comparing with GATE (speed-up factor between 120 and 680). These findings show that the analytical irradiator model presented in this work combined with the µ-RayStation MC dose engine accurately computes dose for the XRAD225Cx irradiator. The improvements in calculation time and availability of functionality and tools for managing, planning and evaluating the irradiation makes this platform very useful for pre-clinical irradiation research.

Enhancement of electron-beam surface dose with an electron multi-leaf collimator (eMLC): a feasibility study

Use of a water-equivalent bolus in electron-beam radiotherapy is sometimes impractical and non-hygienic. Therefore, the feasibility of applying adjacent narrow beams for producing high surface dose electron beams without a bolus was investigated. Depth dose curves and profiles in water were calculated and measured for 6 and 9 MeV electron-beam segments (width 0.3-1.5 cm, length 10 cm) for source-to-surface distances (SSD) 102 and 105 cm. Segment shaping was performed with an add-on electron multi-leaf collimator prototype attached to the Varian 2100 C/D linac. Dose calculations were performed with the Voxel Monte Carlo++ algorithm. Resulting dose distributions in typical clinical cases were compared with the bolus technique. With a composite segmental field with 1.0 cm wide segments the surface dose was over 90% of the depth dose maximum for both energies. The build-up area practically disappeared with a 0.5 cm wide single beam. This led to decrease in the therapeutic range for composite fields with segment widths smaller than 1.0 cm. The new technique yielded similar surface doses as the bolus technique. The photon contamination was 4% with a 9 x 10 cm(2) field (1.0 cm wide segments) compared to 1% for the respective open field with 9 MeV with a bolus. The calculated dose agreed within 2 mm and 3% of the measured dose in 93.7% and 85.2% of the voxels. Adjacent narrow eMLC beams with a 1.0 cm width are suitable to produce electron fields with high surface dose. Despite a slight nonuniformity in the surface profiles in the lateral part of the field at SSD 102 cm, surface dose and target coverage are comparable with the bolus technique.

Observation of the alpha particle "Knock-On" neutron emission from magnetically confined DT fusion plasmas

Suprathermal fuel ions from alpha-particle knock-on collisions in fusion DT plasmas are predicted to cause a weak feature in the neutron spectrum of d+t-->alpha+n. The knock-on feature has been searched for in the neutron emission of high ( >1 MW) fusion-power plasmas produced at JET and was found using a magnetic proton recoil type neutron spectrometer of high performance. Measurement and predictions agree both in absolute amplitude and in plasma-parameter dependence, supporting the interpretation and model. Moreover, the results provide input to projecting alpha-particle diagnostics for future self-heated fusion plasmas.